Targeted therapies in rheumatoid arthritis: Focus on rituximab

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 325-333

  Teng, Yko ^a   van Laar, J M ^a   Huizinga, T W J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti CD20 monoclonal antibodies; B cell depletion; References; Rheumatoid arthritis; Rituximab

Indexed keywords

EID: 77950833802     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Approval Rituxan for rheumatoid arthritis. Accessed April 2007. URL: http://www.fda.gov/cder/biologics/biologics_table.htm
2. Alessandri C, Bombardieri M, Papa N, et al. 2004. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following antiTNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis, 63:1218-21.
3. Aletaha D, Smolen JS. 2002. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol, 29:1631-8.
4. Alvarez C, Brown B, Aristides M, et al. 2006. Cost analysis of introducing rituximab as a new treatment approach for rheumatoid arthritis: the Spanish perspective. EULAR, Abstract no. 0521. 2006.
5. Bathon JM, Martin RW, Fleischmann RM, et al. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med, 343:1586-93.
6. Cerny T, Borisch B, Introna M, et al. 2002. Mechanism of action of rituximab. Anticancer Drugs, 13(Suppl2):S3-10.
7. Cohen SB, Emery P, Greenwald MW, et al. 2006. rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum, 54:2793-806.
8. Coiffier B, Lepage E, Briere J, et al. 2002, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 346:235-42.
9. Dorner T, Burmester GR. 2003. The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol, 15:246-52.
10. Edwards JC, Leandro MJ, Cambridge G. 2005. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr Dir Autoimmun, 8:175-92.
11. Edwards JC, Cambridge G. 2001. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 40:205-11.
12. Edwards JC, Leandro MJ, Cambridge G. 2004a. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am, 30:393-403, viii.
13. Edwards JC, Szczepanski L, Szechinski J, et al. 2004b. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med, 350:2572-81.
14. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum, 54:1390-400.
15. Ernst JA, Li H, Kim HS, et al. 2005. Isolation and characterization of the B-cell marker CD20. Biochemistry, 44:15150-8.
16. Fleischmann R, Emery P, Filipowicz-Sosnowska A, et al. 2005. Coadministration of glucocorticoids does not influence efficacy of, but reduces infusion reactions to, rituximab in rheumatoid arthritis: results from the Dancer study. EULAR.
17. Gao IK, Haas-Wohrle A, Mueller KG, et al. 2005. Determination of antiCCP antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann Rheum Dis, 64:1516-7.
18. Gendreau RM. 2001. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apher, 5:79-83.
19. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF, et al. 2007. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med, 146:406-15.
20. Goldenberg DM. 2006. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther, 6:1341-53.
21. Hansen A, Gosemann M, Pruss A, et al. 2004. Abnormalities in peripheral B cell memory of patients with primary Sjogren's syndrome. Arthritis Rheum, 50:1897-908.
22. Holman HR, Kunkel HG. 1957. Affinity between the lupus erythematosus serum factor and cell nuclei and nucleoprotein. Science, 126:162-3.
23. Isenberg DA, Maddison PJ, Woo P, et al. 2005. Oxford Textbook of Rheumatology, Third edition.
24. Kastbom A, Strandberg G, Lindroos A, et al. 2004. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis, 63:1085-9.
25. Keystone E, Emery P, Peterfy CD, et al. 2006. Prevention of joint structural damage at 1 year with rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX study). EULAR 2006, abstract OP0016.
26. Keystone E, Fleischmann R, Emery P, et al. 2006. Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors. EULAR 2006, Abstract 0125.
27. Kielhorn A, Bombardieri S, Aultman R, et al. 2006. rituximab improves health-related quality of life as measured by the SF-36: domain score results from the REFLEX study. EULAR, Abstract 0126. 2006.
28. Kruithof E, Baeten D, De Rycke L, et al. 2005. Synovial histopathology of psoriatic arthritis, both oligoand polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther, 7:R569-80.
29. Leandro MJ, Cambridge G, Ehrenstein MR, et al. 2006. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum, 54:613-20.
30. Leandro MJ, Cooper N, Cambridge G, et al. 2006. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford).
31. Leandro MJ, Edwards JC, Cambridge G. 2002. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis, 61:883-8.
32. Lewis G, Porter D, Brown B, et al. 2006. Economic consequences of providing rituximab as a new therapeutic option for rheumatoid arthritis in the UK. EULAR 2006, Abstract 0552.
33. Lipsky PE. 2001. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol, 2:764-6.
34. Llorente L, Richaud-Patin Y, Fior R, et al. 1994. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum, 37:1647-55.
35. Mabthera: Summary of product characteristics. Accessed April 2007. URL: http://www.emea.eu.int/humandocs/humans/EPAR/mabthera
36. Maetzel A, Wong A, Strand V, et al. 2000. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford), 39:975-81.
37. Maini R, St Clair EW, Breedveld F, et al. 1999. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet, 354:1932-9.
38. Maloney DG, Smith B, Rose A. 2002. rituximab: mechanism of action and resistance. Semin Oncol, 29:(Suppl2):2-9.
39. McLaughlin P. 2001. rituximab: perspective on single agent experience, and future directions in combination trials. Crit Rev Oncol Hematol, 40:3-16.
40. Mimori T. 2005. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med, 44:1122-6.
41. Ng CM, Bruno R, Combs D, et al. 2005. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol, 45:792-801.
42. Pavelka K, Emery P, Filipowicz-Sosnowska A, et al. 2005. Efficacy and safety following repeated courses of rituximab in patients with active rheumatoid arthritis. EULAR 2005.
43. Roll P, Palanichamy A, Kneitz C, et al. 2006. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum, 54:2377-86.
44. Rose HM, Ragan C, Pearce E, et al. 1948. Differential agglutination of normal and sensitized sheep erythrocytes by sera ofpatients with rheumatoid arthritis. Proc Soc Exo Biol Med, 68:1-6.
45. Silverman GJ. 2006. Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum, 54:2356-67.
46. Smith MR. 2003. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 22:7359-68.
47. Snowden JA, Passweg J, Moore JJ, et al. 2004. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol, 31:482-8.
48. Storek J, Saxon A. 1992. Reconstitution of B cell immunity following bone marrow transplantation. Bone Marrow Transplant, 9:395-408.
49. Strand V, Balbir-Gurman A, Pavelka K, et al. 2005. Two-year improvements in physical function reflect sustained benefit in rheumatoid arthritis patients receiving a single course of rituximab and methotrexate. EULAR 2005.
50. Teeling JL, Mackus WJ, Wiegman LJ, et al. 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol, 177:362-71.
51. Teng YK, Hashemi M, Levarht EW, et al. 2007. Recruitment of B lymphocytes into the periphery is associated with disease activity in patients with refractory rheumatoid arthritis. Ann Rheum Dis, 66:(Suppl1):6-69.
52. Teng YK, Ioan-Facsinay A, van Laar JM. 2007. CD20 epitope masking by rituximab: comment on the article by Gunnarsson et al. Arthritis Rheum, in press.
53. Teng YK, Levarht EW, Hashemi M, et al. 2007. B-cell activity in synovium predicts responsiveness to rituximab in patients with refractory rheumatoid arthritis. Arthritis Rheum, in press.
54. Tsokos GC. 2004. B cells, be gone B-cell depletion in the treatment of rheumatoid arthritis. N Engl J Med, 350:2546-8.
55. van der Kooij SM, Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. 2007. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent-onset rheumatoid arthritis treated according to the Disease Activity Score. Ann Rheum Dis, in press.
56. van Gaalen FA, Visser H, Huizinga TW. 2005. A comparison of the diagnostic accuracy and prognostic value of the first and second anticyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis, 64:1510-2.
57. van Oosterhout M, Levarht EW, Sont JK, et al. 2005. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis, 64:537-43.
58. Verburg RJ, Kruize AA, van den Hoogen FH, et al. 2001. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy. Arthritis Rheum, 44:754-60.
59. Vos K, Thurlings RM, Wijbrandts CA, et al. 2007. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum, 56:772-8.
60. Vossenaar ER, van Venrooij WJ. 2004. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther, 6:107-11.
61. Weinblatt ME, Keystone EC, Furst DE, et al. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum, 48:35-45.
62. Weinblatt ME, Kremer JM, Bankhurst AD, et al. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 340:253-9.